Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon release. GLP-1 derivatives exhibit promising therapeutic efficacy in treating type 2